5-([1,4]Diazepane-1-sulfonyl)-isoquinoline

ID: ALA38380

Cas Number: 103745-39-7

PubChem CID: 3547

Product Number: F134784, Order Now?

Max Phase: Phase

Molecular Formula: C14H17N3O2S

Molecular Weight: 291.38

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Fasudil | AT 877 | AT-877 | HA 1077 | HA-1077 | NSC-759827 | ZK-258594 | Fasudil|103745-39-7|ha-1077|HA 1077|AT 877|AT-877|HA1077|Fasudil [INN]|Fasudilum|1H-1,4-Diazepine, hexahydro-1-(5-isoquinolinylsulfonyl)-|1-(5-Isoquinolinesulfonyl)homopiperazine|5-(1,4-diazepan-1-ylsulfonyl)isoquinoline|5-(1,4-diazepane-1-sulfonyl)isoquinoline|AT877|Hexahydro-1-(5-isoquinolinylsulfonyl)-1H-1,4-diazepine|Q0CH43PGXS|5-(1,4-DIAZEPAN-1-SULFONYL)ISOQUINOLINE|NSC-759827|Fasudil dihydrochloride|CHEMBL38380|ZK-258Show More⌵

Synonyms from Alternative Forms(2): Fasudil hydrochloride | Fasudil

Canonical SMILES:  O=S(=O)(c1cccc2cnccc12)N1CCCNCC1

Standard InChI:  InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2

Standard InChI Key:  NGOGFTYYXHNFQH-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 20 22  0  0  0  0  0  0  0  0999 V2000
    0.5167   -1.1167    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.5292    0.2875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9625   -1.1042    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7500    1.0083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5167   -2.2750    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.7167   -1.1042    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0333   -2.5167    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.2375    2.4333    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7500    2.4333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3000   -2.5375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8458    0.0875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6708    0.9958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4083    0.0875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7083   -3.1542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9917    3.1500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3458   -1.0792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0042    0.3000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6833    2.4333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2375    0.9958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5292    3.1708    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  1  1  0
  4  2  2  0
  5  1  2  0
  6  1  2  0
  7 14  1  0
  8 19  1  0
  9  4  1  0
 10  3  1  0
 11  3  1  0
 12  2  1  0
 13 11  1  0
 14 10  1  0
 15  9  1  0
 16 13  1  0
 17  4  1  0
 18 12  2  0
 19 17  2  0
 20 18  1  0
 16  7  1  0
  9 20  2  0
 15  8  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA38380

   FASUDIL

2. Alternative Forms:

   

   ALA38380

   Fasudil Hydrochloride
3. 

   ALA38380

   HA-1077 dihydrochloride
4. 

   ALA38380

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: Yes

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 291.38

Molecular Weight (Monoisotopic): 291.1041

AlogP: 1.22

#Rotatable Bonds: 2

Polar Surface Area: 62.30

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 8.04

CX LogP: 0.32

CX LogD: -0.40

Aromatic Rings: 2

Heavy Atoms: 20

QED Weighted: 0.90

Np Likeness Score: -1.64

References

1. McGovern SL, Shoichet BK..  (2003)  Kinase inhibitors: not just for kinases anymore.,  46  (8): [PMID:12672248] [10.1021/jm020427b]

2. Iwakubo M, Takami A, Okada Y, Kawata T, Tagami Y, Sato M, Sugiyama T, Fukushima K, Taya S, Amano M, Kaibuchi K, Iijima H..  (2007)  Design and synthesis of rho kinase inhibitors (III).,  15  (2): [PMID:17084087] [10.1016/j.bmc.2006.10.028]

3. Woodard CL, Keenan SM, Gerena L, Welsh WJ, Geyer JA, Waters NC..  (2007)  Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk.,  17  (17): [PMID:17588749] [10.1016/j.bmcl.2007.06.032]

4. Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S..  (2007)  A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.,  104  (51): [PMID:18077363] [10.1073/pnas.0708800104]

5. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P..  (2007)  The selectivity of protein kinase inhibitors: a further update.,  408  (3): [PMID:17850214] [10.1042/bj20070797]

6. Jacobs M, Hayakawa K, Swenson L, Bellon S, Fleming M, Taslimi P, Doran J..  (2006)  The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.,  281  (1): [PMID:16249185] [10.1074/jbc.m508847200]

7. Morwick T, Büttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E..  (2010)  Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,  53  (2): [PMID:20000469] [10.1021/jm9014263]

8. Wu F, Büttner FH, Chen R, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Paw Z, Prokopowicz A, Shih CK, Snow R, Young E, Cywin CL..  (2010)  Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.,  20  (11): [PMID:20462760] [10.1016/j.bmcl.2010.04.070]

9. Qin J, Lei B, Xi L, Liu H, Yao X..  (2010)  Molecular modeling studies of Rho kinase inhibitors using molecular docking and 3D-QSAR analysis.,  45  (7): [PMID:20347188] [10.1016/j.ejmech.2010.02.059]

10. Davies SP, Reddy H, Caivano M, Cohen P..  (2000)  Specificity and mechanism of action of some commonly used protein kinase inhibitors.,  351  (1): [PMID:10998351] [10.1042/0264-6021:3510095]

11. PubChem BioAssay data set, 

12. PubChem BioAssay data set, 

13. Rode HB, Sos ML, Grütter C, Heynck S, Simard JR, Rauh D..  (2011)  Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor.,  19  (1): [PMID:21130659] [10.1016/j.bmc.2010.11.007]

14. Ray P, Wright J, Adam J, Bennett J, Boucharens S, Black D, Cook A, Brown AR, Epemolu O, Fletcher D, Haunso A, Huggett M, Jones P, Laats S, Lyons A, Mestres J, de Man J, Morphy R, Rankovic Z, Sherborne B, Sherry L, van Straten N, Westwood P, Zaman GZ..  (2011)  Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.,  21  (1): [PMID:21145740] [10.1016/j.bmcl.2010.11.060]

15. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A..  (2010)  Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.,  23  (1): [PMID:20014752] [10.1021/tx900326k]

16. PubChem BioAssay data set, 

17. PubChem BioAssay data set, 

18. PubChem BioAssay data set, 

19. Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL, Smith GK, Chen Z, Webb C, Khandekar S, Yi T, Kirkpatrick R, Dul E, Jolivette L, Marino JP, Willette R, Lee D, Hu E..  (2007)  Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.,  320  (1): [PMID:17018693] [10.1124/jpet.106.110635]

20. PubChem BioAssay data set, 

21. PubChem BioAssay data set, 

22. Lavogina D, Kalind K, Bredihhina J, Hurt M, Vaasa A, Kasari M, Enkvist E, Raidaru G, Uri A..  (2012)  Conjugates of 5-isoquinolinesulfonylamides and oligo-D-arginine possess high affinity and selectivity towards Rho kinase (ROCK).,  22  (10): [PMID:22521647] [10.1016/j.bmcl.2012.03.101]

23. Jester BW, Gaj A, Shomin CD, Cox KJ, Ghosh I..  (2012)  Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen.,  55  (4): [PMID:22257127] [10.1021/jm201265f]

24. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

25. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ..  (2013)  A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.,  451  (2): [PMID:23398362] [10.1042/bj20121418]

26. PubChem BioAssay data set, 

27. Rohe A, Göllner C, Wichapong K, Erdmann F, Al-Mazaideh GM, Sippl W, Schmidt M..  (2013)  Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.,  61  [PMID:22770610] [10.1016/j.ejmech.2012.06.007]

28. Takahashi N, Takeda K, Imai M..  (2013)  Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.,  21  (19): [PMID:23953690] [10.1016/j.bmc.2013.07.039]

29. Unpublished dataset, 

30. Guan R, Xu X, Chen M, Hu H, Ge H, Wen S, Zhou S, Pi R..  (2013)  Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors.,  70  [PMID:24211637] [10.1016/j.ejmech.2013.10.048]

31. PubChem BioAssay data set, 

32. Pireddu R, Forinash KD, Sun NN, Martin MP, Sung SS, Alexander B, Zhu JY, Guida WC, Schönbrunn E, Sebti SM, Lawrence NJ..  (2012)  Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).,  3  (6): [PMID:23275831] [10.1039/c2md00320a]

33. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

34. Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S..  (2007)  A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.,  104  (51): [PMID:18077363] [10.1073/pnas.0708800104]

35. Sanoh S, Horiguchi A, Sugihara K, Kotake Y, Tayama Y, Ohshita H, Tateno C, Horie T, Kitamura S, Ohta S..  (2012)  Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.,  40  (2): [PMID:22048522] [10.1124/dmd.111.040923]

36. Green J, Cao J, Bandarage UK, Gao H, Court J, Marhefka C, Jacobs M, Taslimi P, Newsome D, Nakayama T, Shah S, Rodems S..  (2015)  Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.,  58  (12): [PMID:26039570] [10.1021/acs.jmedchem.5b00424]

37. Sikorska J, Codutti L, Skjrven L, Elshorst B, Saez-Ameneiro R, Angelini A, Monecke P, Carlomagno T.  (2015)  Identification of new hit scaffolds by INPHARMA-guided virtual screening,  6  (8): [10.1039/C5MD00116A]

38. Donegan RK, Lieberman RL..  (2016)  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.,  59  (3): [PMID:26356532] [10.1021/acs.jmedchem.5b00828]

39. WHO Anatomical Therapeutic Chemical Classification, 

40. Klaeger S, Heinzlmeir S and Wilhelm M et al.  (2017)  The target landscape of clinical kinase drugs.,  358  (6367): [PMID:29191878] [10.1126/science.aan4368]

41. Wienen-Schmidt B, Jonker HRA, Wulsdorf T, Gerber HD, Saxena K, Kudlinzki D, Sreeramulu S, Parigi G, Luchinat C, Heine A, Schwalbe H, Klebe G..  (2018)  Paradoxically, Most Flexible Ligand Binds Most Entropy-Favored: Intriguing Impact of Ligand Flexibility and Solvation on Drug-Kinase Binding.,  61  (14): [PMID:29909615] [10.1021/acs.jmedchem.8b00105]

42. Abbhi V, Saini L, Mishra S, Sethi G, Kumar AP, Piplani P..  (2017)  Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma.,  25  (21): [PMID:29033348] [10.1016/j.bmc.2017.09.045]

43. Domokos D, Fülöp F, Falkay G, Gáspár R..  (2018)  Effects of newly synthetized isoquinoline derivatives on rat uterine contractility and ROCK II activity.,  28  (3): [PMID:29269216] [10.1016/j.bmcl.2017.12.017]

44. Unpublished dataset, 

45. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson.  (2020)  Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,  [10.1101/2020.04.21.054387]

46. Dayal N, Mikek CG, Hernandez D, Naclerio GA, Yin Chu EF, Carter-Cooper BA, Lapidus RG, Sintim HO..  (2019)  Potently inhibiting cancer cell migration with novel 3H-pyrazolo[4,3-f]quinoline boronic acid ROCK inhibitors.,  180  [PMID:31330446] [10.1016/j.ejmech.2019.06.089]

47. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

48. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

49. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

50. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

51. Ellen Van Damme.  (2021)  Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity,  [10.6019/CHEMBL4651402]

52. Cheng KJ,Hsieh CM,Nepali K,Liou JP.  (2020)  Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.,  63  (19.0): [PMID:32482069] [10.1021/acs.jmedchem.9b01033]

53. Hu Z,Wang C,Sitkoff D,Cheadle NL,Xu S,Muckelbauer JK,Adam LP,Wexler RR,Quan ML.  (2020)  Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.,  30  (21.0): [PMID:32805407] [10.1016/j.bmcl.2020.127474]

54. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius.  (2021)  HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators,  [10.6019/CHEMBL4808148]

55. Lee S, Kim J, Jo J, Chang JW, Sim J, Yun H..  (2021)  Recent advances in development of hetero-bivalent kinase inhibitors.,  216  [PMID:33730624] [10.1016/j.ejmech.2021.113318]

56. Martín-Cámara O, Arribas M, Wells G, Morales-Tenorio M, Martín-Requero Á, Porras G, Martínez A, Giorgi G, López-Alvarado P, Lastres-Becker I, Menéndez JC..  (2022)  Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis.,  65  (3.0): [PMID:34985276] [10.1021/acs.jmedchem.1c01255]

57. Mancini RS, Barden CJ, Weaver DF, Reed MA..  (2021)  Furazans in Medicinal Chemistry.,  64  (4.0): [PMID:33569941] [10.1021/acs.jmedchem.0c01901]

58. Feng Y, LoGrasso PV, Defert O, Li R..  (2016)  Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.,  59  (6): [PMID:26486225] [10.1021/acs.jmedchem.5b00683]

59. Sutherland JJ, Yonchev D, Fekete A, Urban L..  (2023)  A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.,  14  (1): [PMID:37468498] [10.1038/s41467-023-40064-9]

Source

Source(11):

• Scientific Literature
• PubChem BioAssays
• Clinical Candidates
• USP Dictionary of USAN and International Drug Names
• Gene Expression Atlas Compounds
• AstraZeneca Deposited Data
• WHO Anatomical Therapeutic Chemical Classification
• Kuster lab chemical proteomics drug profiling
• SARS-CoV-2 Screening Data 2020-21
• IMI-CARE SARS-CoV-2 Data
• Fraunhofer HDAC6